NDLI: Neue Behandlungsansätze beim Mammakarzinom.

Please wait, while we are loading the content...

Neue Behandlungsansätze beim Mammakarzinom.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Spirig, Christian Thürlimann, Beat Huober, Jens
Description	Author Affiliation: Spirig C ( Senologie Zentrum Ostschweiz, Kantonsspital St. Gallen, Rorschacherstrasse 170, St. Gallen. christian.spirig@kssg.ch)
Abstract	A great step was taken in the treatment of the prognostically unfavourable group of Her2-positive breast cancer in the past years with the introduction of the targeted therapy with trastuzumab, which showed significant increase in median survival in the metastatic and adjuvant setting of Her2-positive breast cancer patients. Lapatinib, an oral HER2-tyrosine kinase inhibitor, showed activity in patients with breast cancer progression after trastuzumab. The role of lapatinib in the adjuvant setting will be examined in the ongoing, multicenter, prospective, four-arm ALTTO-trial, which compares the current standard treatment of one year trastuzumab against lapatinib, the combination of trastuzumab and lapatinib and an arm with sequential trastuzumab followed by lapatinib. Another promising treatment option is the VEGF-antibody bevacizumab, which blocks tumor-mediated angiogenesis leading to oxygen undersupply and finally growth inhibition of the tumor. Concerning treatment decision, two ongoing prospective trials in the USA and Europe are eagerly awaited, which examine the role of gene-array assessment in terms of risk stratification and finally tailoring adequate treatment.
File Format	HTM / HTML
ISSN	00405930
Issue Number	4
Volume Number	65
e-ISSN	16642864
Journal	Therapeutische Umschau
Language	German
Publisher	Hogrefe Verlag
Publisher Date	2008-04-01
Publisher Place	Switzerland
Access Restriction	Subscribed
Subject Keyword	Discipline Therapeutics Antibodies, Monoclonal Therapeutic Use Antineoplastic Agents Breast Neoplasms Drug Therapy Paclitaxel Protein Kinase Inhibitors Quinazolines Receptor, Erbb-2 Antagonists & Inhibitors Vascular Endothelial Growth Factor A Adverse Effects Antibodies, Monoclonal, Humanized Antineoplastic Combined Chemotherapy Protocols Bevacizumab Genetics Surgery Chemotherapy, Adjuvant Female Gene Expression Regulation, Neoplastic Drug Effects Humans Prognosis Trastuzumab English Abstract Journal Article
Alternative Title	New treatment approaches in breast cancer
Content Type	Text
Resource Type	Article
Subject	Medicine

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in